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Objective: To develop a method for proﬁling the collective populations targeted for recruitment by multi-
ple clinical studies addressing the same medical condition using one eligibility feature each time.
Methods: Using a previously published database COMPACT as the backend, we designed a scalable
method for visual aggregate analysis of clinical trial eligibility features. This method consists of four mod-
ules for eligibility feature frequency analysis, query builder, distribution analysis, and visualization,
respectively. This method is capable of analyzing (1) frequently used qualitative and quantitative features
for recruiting subjects for a selected medical condition, (2) distribution of study enrollment on consecu-
tive value points or value intervals of each quantitative feature, and (3) distribution of studies on the
boundary values, permissible value ranges, and value range widths of each feature. All analysis results
were visualized using Google Charts API. Five recruited potential users assessed the usefulness of this
method for identifying common patterns in any selected eligibility feature for clinical trial participant
selection.
Results: We implemented this method as a Web-based analytical system called VITTA (Visual Analysis
Tool of Clinical Study Target Populations). We illustrated the functionality of VITTA using two sample
queries involving quantitative features BMI and HbA1c for conditions ‘‘hypertension’’ and ‘‘Type 2 diabe-
tes’’, respectively. The recruited potential users rated the user-perceived usefulness of VITTA with an
average score of 86.4/100.
Conclusions: We contributed a novel aggregate analysis method to enable the interrogation of common
patterns in quantitative eligibility criteria and the collective target populations of multiple related clinical
studies. A larger-scale study is warranted to formally assess the usefulness of VITTA among clinical inves-
tigators and sponsors in various therapeutic areas.
 2015 Elsevier Inc. All rights reserved.1. Introduction
Well-designed clinical study protocols are essential for generat-
ing high-quality medical evidence [1]. However, studies are often
criticized for lacking generalizability, or external validity [2–16].
Because population representativeness is an important aspect of
clinical research generalizability, study designers should justify
the tradeoffs between internal validity and external validity that
arise from their choices of eligibility criteria. Biased or overly
restrictive eligibility criteria may (1) exclude patients who may
need or beneﬁt from the research [4,5], and (2) lead to an overes-
timate of the efﬁcacy of an intervention [10]. For example, accord-
ing to Schmidt et al. [12], almost none of their analyzed studies on
secondary prevention of cardiovascular events justiﬁed the appliedexclusion criteria, which excluded 21–97% of the female target
population. Similarly, Zimmerman et al. [15] reported that approx-
imately 32–47% of patients with major depressive disorder would
have been excluded by two most commonly used cutoff values of
the Hamilton Rating Scale for Depression in antidepressant efﬁcacy
trials, i.e., 18 and 20.
When designing clinical studies, investigators often reuse eligi-
bility criteria from previous protocols of related studies. One of our
previously published papers also discovered that many clinical
studies, especially those on the same medical condition, use simi-
lar or identical eligibility criteria [17]. Therefore, we hypothesize
that the generalizability issue might be not only at the level of indi-
vidual studies, but also at the community level in the entire clinical
trial enterprise. Unlike prior work that looks at the generalizability
of one study at a time, we are motivated to assess the collective
generalizability by uncovering collective design patterns for partic-
ipant selection among multiple related clinical trials. Unfortu-
nately, at present there is no method or tool for making such
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this need, recently the National Center for Advancing Translational
Sciences (NCATS) responded to the Institute of Medicine’s review
of the Clinical and Translational Science Awards (CTSA) Program
in the United States and identiﬁed ‘‘lack of a knowledge base for
all types of interventions at the extremes of age as well as within
special populations’’ as one of the weaknesses of the current trans-
lational science enterprise [18]. To help bridge this gap, a comput-
able repository of eligibility features of clinical trials is needed to
analyze the characteristics of the target populations on a large
scale [19].
The study and result registry ClinicalTrials.gov [20] created by
the National Library of Medicine is a valuable public data source.
Since September 27, 2007, all United States-based clinical trials
of FDA-regulated drugs, biological products, or devices have been
mandated to be registered in ClinicalTrials.gov [21]. As of March
18, 2014, 163,285 clinical studies conducted in more than 180
countries were registered in ClinialTrials.gov. Study summaries
are stored in a semi-structured format in the registry, i.e., study
descriptors such as title, phase, and location are organized in struc-
tured ﬁelds. The eligibility criteria are usually organized as para-
graphs of free-text or as bullet lists.
The ClinicalTrials.gov is a preferred resource to be transformed
into a computable repository of reusable knowledge of clinical trial
designs. However, there is little published work on building a com-
putable repository from study summaries on ClinicalTrials.gov.
Tasneem et al. developed the Aggregate Analysis of ClinicalTri-
als.gov (AACT) database as a publicly accessible analysis dataset
derived from ClinicalTrials.gov [22]. Using AACT data, clinical trials
in various domains have been systematically analyzed, e.g., infec-
tious diseases [23], oncology [24], and diabetes [25], to name a
few. AACT allows selection and aggregation of trials by study
descriptors, such as study status, phase, and intervention type,
but not by ﬁne-grained clinical characteristics of the target popu-
lation. As studies often limit eligibility to permissible ranges of
quantitative features as age, BMI, HbA1c, and blood glucose level
[26], investigators or policy makers may be interested in analyzing
such quantitative features across studies addressing the same
medical condition, with questions like ‘‘what is the range of BMI val-
ues that are permitted across interventional studies on Type 2 diabe-
tes?’’ However, as most of the eligibility criteria are in
unstructured text, it remains difﬁcult to support these analyses
in a programmatic, accurate and scalable way. Hence, to date, there
is a paucity of analyses on the quantitative eligibility features of
target populations of existing studies, and consequently a lack of
capacity to optimize the eligibility criteria deﬁnition for future
clinical studies based on past studies.
We have developed methods for parsing eligibility features
from free-text eligibility criteria [17,27–41] and the derived fre-
quent eligibility features across ClinicalTrials.gov study summaries
have produced promising results for searching and indexing stud-
ies [29], probing disease relatedness [30], and clustering studies
with similar eligibility criteria [17]. Enabled by these techniques,
we have created a database of discrete clinical trial eligibility fea-
tures extracted from ClinicalTrials.gov called COMPACT (Common-
alities in Target Populations of Clinical Trials) [42], which allows
users to ﬂexibly query sets of clinical studies (e.g., Type 2 diabetes
studies) on their shared eligibility features (e.g., HbA1c or BMI) and
attributes (e.g., allowed value range for HbA1c or BMI). In addition,
we have developed a distribution-based method for proﬁling clin-
ical trial target populations across sets of studies [43]. Meanwhile,
as one of the state-of-the-art methods for discovering knowledge
from Big Data [44,45], interactive visual query interfaces can be
employed to further support ﬂexible proﬁling of target populations
of sets of clinical studies and to investigate the generalizability of
these studies. It has been used for tasks similar to proﬁling targetpopulations, such as visualizing alternative disease progression
paths for a group of patients similar to a query patient [46], and
for visual analysis of clinical event patterns through a combination
of a graphical query interface, pattern mining and visualization
techniques [47]. Therefore, we enhanced our COMPACT database
of study summaries with visualization of the distributions of sets
of clinical studies along any single quantitative eligibility feature.
To the best of our knowledge, this effort represents one of the ear-
liest attempts to perform aggregate analyses of clinical trial eligi-
bility criteria design patterns. Fig. 1 illustrates the design of the
methodology framework, which integrates text mining, data ware-
housing, and data visual analytics for rich information made avail-
able by ClinicalTrials.gov. This pipeline can help clinical trial
designers more easily understand collective design patterns in
clinical trial eligibility criteria across multiple related clinical trial
studies. On this basis, our system can increase the transparency
of hidden eligibility criteria design biases at the clinical research
community level. Our system supports ﬂexible study selection
using multiple study descriptors, such as study type, study design,
intervention type, phase, condition, gender, and age range. We
hypothesized that our method could identify understudied popula-
tion subgroups whose value ranges for certain quantitative eligibil-
ity features were systematically excluded or overly researched
according to analyses of eligibility criteria speciﬁcations. Our pre-
liminary user evaluation conﬁrmed this hypothesis and the value
of our method for improving the transparency of clinical trial par-
ticipant selection decisions.
The remainder of the paper is organized as follows. Section 2
ﬁrst describes the visual aggregate analysis system of eligibility
features of clinical trials and how a user interacts with it, and then
delineates the methods used to develop and evaluate the system.
In Section 3, we use Type 2 diabetes and hypertension as example
conditions to illustrate the functionalities of the system. We also
present the results of a preliminary evaluation with a convenience
sample of ﬁve potential users of the system. Finally, we discuss the
implication and the limitations of this work in Section 4 and draw
conclusions in Section 5.2. Methods
Previously, we introduced a novel database called COMPACT,
which stores metadata and parsed eligibility criteria of study sum-
maries in ClinicalTrials.gov [42]. It supports retrieval of readily
analyzable eligibility features, quantitative or qualitative, from sets
of studies. On this basis, we designed an interactive visual analysis
system to aggregate target populations of sets of clinical studies.
The potential users of this system include clinical investigators,
study sponsors and policy makers. Table 1 presents the glossary
of terms that are frequently used in this paper.
Our system enables a user to select a medical condition, one of
the quantitative eligibility features frequently seen in studies on
that medical condition and other additional study descriptors
(e.g., study type, study design, intervention type) to perform ﬁve
analyses: (1) distribution of number of studies over consecutive
value points or non-overlapping value intervals within user-speci-
ﬁed value range of the selected quantitative eligibility feature (e.g.,
over each 0.5% of HbA1c); (2) distribution of enrollment over those
value points or value intervals; (3) distribution of number of stud-
ies over boundary values (e.g., lower bound of HbA1c as 7.0%); (4)
distribution of number of studies over permissible value ranges
(e.g., BMI between 15 and 25 kg/m2); and (5) distribution of num-
ber of studies over value range widths (e.g., the value range width
for HbA1c between 7% and 10% is 10  7 = 3). Fig. 2 illustrates the
comparison between information provided by the ClinicalTri-
als.gov and our system called VITTA (Visual Analysis Tool of Clini-
Fig. 1. The methodology framework.
Table 1
The glossary.
Term Description
Quantitative features Eligibility criteria with a permissible numeric (continuous) value range requirement for participants, e.g., ‘‘BMI < 30 kg/m2’’
Qualitative features Eligibility criteria that accept one of a set of value options, e.g., ‘‘with acute ischemic stroke’’ (yes or no)
Value spectrum The collective value range of a quantitative feature in selected studies that use the feature for eligibility determination
User-speciﬁed value
range
The value range of a quantitative feature speciﬁed by the user for analyzing the distribution of studies and enrollment. For example, a value
range of HbA1c can be ‘‘4–12%’’
Value intervals Evenly (based on the user-speciﬁed width) or unevenly (based on the actual boundary values) divided smaller bins in the user-speciﬁed value
range
Permissible value
range
The value range speciﬁed by an eligibility criterion. For example, the permissible value range for criterion ‘‘age between 15 and 40’’ is [15,40],
where ‘‘[ ]’’ means inclusive
Value range width The difference between the upper bound and lower bound of a permissible value range. For example, the value range width for the criterion
‘‘age between 15 and 40’’ is 25 (=40  15)
Boundary value The threshold value(s) of a quantitative feature in an eligibility criterion, e.g., the boundary values for the criterion ‘‘age between 15 and 40’’ are
15 and 40
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analyze the aggregate target populations of Type 2 diabetes studies
in ClinicalTrials.gov may search for studies whose condition is
‘‘Type 2 diabetes.’’ They would then review the summary of each
of the studies returned, look for ‘‘HbA1c’’ in the eligibility criteria
section, note the permissible value range and ﬁnally manually
aggregate all the values retrieved. In contrast, our system can auto-
matically group sets of studies and summarize such information
from the pre-processed study summaries in the COMPACT
database.
The workﬂow (Fig. 3) for a user is as follows: (1) select a med-
ical condition and specify the number of frequent features to
retrieve; (2) select a quantitative eligibility feature among the
most frequent quantitative features of the studies on the condition
selected in step (1); (3) specify a value range of the selected quan-
titative feature and optionally one or more study descriptors to fur-
ther restrict the set of studies; (4) choose a type of analysis on the
quantitative feature; and (5) receive the visual query results.
For example, if a user chooses ‘‘Type 2 diabetes’’ as the condi-
tion and sets the number of frequent features to retrieve as ‘‘10’’,
the system returns a list of 10 most frequent quantitative eligibility
features extracted from Type 2 diabetes studies. From this list, the
user may choose ‘‘HbA1c.’’ The user is then asked to specify the
value range of interest for HbA1c and additional characteristics
for the studies to be included in the analysis, such as study type,study design, intervention type, or patient age range. The user
may formulate a query as ‘‘distribution of enrollment in randomized
studies in Phase 2/3 on Type 2 diabetes sponsored by industry over
value intervals of HbA1c between 1% and 14%.’’ The width of value
intervals can be ﬁxed or varying. If the user speciﬁes a width
(e.g., ‘‘0.5’’), the range 1–14% is evenly divided into value intervals
of the samewidth (e.g., [1%,1.5%], [1.5%,2%], . . . , [13.5%,14%]). Alter-
natively, the user may perform this analysis on varying-width
value intervals, which are generated based on the actual boundary
values of HbA1c in the selected studies. Hypothetically, this search
would include studies NCT00374907 (enrollment: 156) and
NCT00097084 (enrollment: 324). The range of HbA1c in
NCT00374907 is 6–8% and in NCT00097084 it is 7–11%. These four
boundary values (6%, 7%, 8%, 11%) would be used to divide the
range 1–14% into ﬁve value intervals of varying widths: [1%,6%],
[6%,7%], [7%,8%], [8%,11%], and [11%,14%]. The system would then
analyze the enrollment of the studies that recruit subjects with
HbA1c in each value interval and visualize the result. Table 2
shows the distribution of enrollment (anticipated or actual) for this
example. Column 4 (maximum enrollment) shows the aggregate
enrollment of all the studies in each interval, whereas column 5
(average enrollment) shows the average of study enrollment for
all the studies in each interval.
The system also allows the user to visually identify frequently
or rarely used boundary values, permissible value ranges, and per-
Fig. 2. The comparison between information provided by ClinicalTrials.gov and VITTA.
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The analytical framework underlying this system comprises four
modules: an eligibility feature frequency analysis module, a query
builder, a distribution analysis module, and a visualization module,
each supporting a step of the user’s interaction with the system. In
the rest of this section, we ﬁrst brieﬂy describe how we processed
the study summaries in ClinicalTrials.gov for building the COM-
PACT database. (The design and implementation detail of COM-
PACT are described in [42].) Then we explain in detail the design
and implementation of these four modules.
2.1. Parsing study summaries
From the ClinicalTrials.gov website we downloaded the XML
records of all the studies and transformed data elements of interest
into a computable format using Python programs in four steps: (1)
extract study metadata such as study type, intervention type, study
phase, gender, and age; (2) identify studies for a certain medical
condition; (3) mine frequent eligibility features from free-text eli-
gibility criteria; (4) structure numeric expressions for the frequent
quantitative features. Next, we describe these four steps in detail.
2.1.1. Extracting metadata of studies
From each downloaded XML ﬁle, we extracted study character-
istics and structured the free-text eligibility criteria text using pre-
viously published methods [28,48]. We created a table inCOMPACT and saved the extracted metadata of studies: National
Clinical Trial (NCT) number (a unique ID assigned by ClinicalTri-
als.gov), study type (e.g., interventional, observational), interven-
tion type, study design (i.e., allocation and intervention model for
interventional studies; time perspective for observational studies),
phase, sponsor agency type (e.g., NIH, industry), enrollment status,
start date, gender, minimum age, maximum age, and enrollment.
From COMPACT, we can ﬂexibly retrieve studies with various char-
acteristics, e.g., all the observational diabetes studies sponsored by
NIH.
2.1.2. Identifying studies for a certain medical condition
To retrieve condition-speciﬁc high-frequency eligibility fea-
tures, we obtained all the NCT numbers and the list of 4412 med-
ical conditions listed in ClinicalTrials.gov records [49]. We pre-
indexed the studies of 1311 conditions, each having more than
50 studies in ClinicalTrials.gov at the point of the study. With the
APIs provided by ClinicalTrials.gov, studies using synonyms of
the same condition such as ‘‘heart attack’’ and ‘‘myocardial infarc-
tion’’ were automatically consolidated [50].
2.1.3. Identifying the most frequent eligibility features
We extended a published method for mining frequent tags [28]
to extract frequently used eligibility features from eligibility crite-
ria. A frequent tag is an n-gram completely or partially matching a
UMLS concept to a semantic type most relevant to clinical study
Fig. 3. The workﬂow for a user to interact with VITTA.
Table 2
Distribution of enrollment of two sample studies on varying-widths value intervals of HbA1c.
Value interval Included studies Number of studies Maximum enrollment Average enrollment
[1.0%,6.0%] 0 0 0
[6.0%,7.0%] NCT00374907 1 156 156
[7.0%,8.0%] NCT00374907, NCT00097084 2 480 240
[8.0%,11.0%] NCT00097084 1 324 324
[11.0%,14.0%] 0 0 0
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appears in more than 3% of the studies of a given condition. We
excluded the tags of the semantic type ‘‘Body Part, Organ, or Organ
Component,’’ because they were not informative in this context.
We also divided the features into two groups: qualitative (e.g.,
diagnosis, procedure, or device) and quantitative (e.g., clinical
attribute or laboratory test result). Quantitative features were fur-
ther parsed as described below.
2.1.4. Extracting quantitative features
We used a numeric expression extraction tool called Valx [48]
to structure numeric expressions from free-text eligibility criteria.
To identify the quantitative features and extract numeric expres-
sions, Valx pre-compiled a list of unique quantitative features
using domain knowledge (from online resources such as WebMD
[51], WHO website [52], and web communities for various condi-
tions) and frequent UMLS (Uniﬁed Medical Language System)
[53] concepts with their synonyms, which cover selected semantic
types relevant to quantiﬁable attributes in clinical studies (e.g.,
Clinical Attribute, Laboratory or Test Result, and Quantitative Con-
cept). For each quantitative feature, this pre-compiled list containspossible feature names for uniﬁcation (e.g., HbA1c, A1c, and Glyco-
hemoglobin), a preferred feature name, allowable measurement
units, exception units, a preferred unit for normalization, and a
normal range (with amax_allowed_value and amin_allowed_value).
With the pre-compiled list, Valx uniﬁed different feature names
and normalized heterogeneous measurement units of the same
feature. For example, ‘‘A1c,’’ ‘‘hemoglobin A1c,’’ and ‘‘HbA1c’’ were
all recognized as ‘‘HbA1c.’’
Valx ﬁrst extracted candidate numeric expressions from eligi-
bility criteria text. Then, using regular expression matching, it
structured each candidate numeric expression into four compo-
nents: a candidate quantitative feature, a comparison symbol
(i.e., ‘‘=,’’ ‘‘>,’’ ‘‘<,’’ ‘‘>=,’’ and ‘‘<=’’), a threshold value, and a measure-
ment unit (e.g., ‘‘lb’’ or ‘‘kg’’). For example, from an exclusion crite-
rion ‘‘evidence for Type 2 diabetes, including fasting plasma glucose
greater than or equal to 126 mg/dl or HbA1c greater than 6.5%,’’ we
extracted two numeric expressions: [‘‘Glucose’’, ‘‘>=’’, 126.0, ‘‘mg/
dL’’] and [‘‘HbA1c’’, ‘‘>’’, 6.5, ‘‘%’’]. Valx built n-grams (i.e., continu-
ous subsequence of n words) of the candidate quantitative feature
after removing special characters and punctuation from it. It
removed n-grams composed of only English stop-words or irrele-
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the pre-compiled list of quantitative features and retained if at
least one substring was in the list. It normalized allowable mea-
surement units to enable meaningful aggregation of quantitative
values. Lastly, it performed heuristic rule-based removal of invalid
numeric expressions by comparing the threshold value with the
allowable value range of the quantitative feature speciﬁed in the
pre-compiled list, i.e., the expressions with a threshold value above
max_allowed_value ⁄ 2 or below min_allowed_value/2 were consid-
ered invalid and therefore removed. To unifying the exclusion cri-
teria and inclusion criteria, it converted all numeric expressions in
exclusion criteria to inclusion criteria using negations, such as
replacing ‘‘<’’, ‘‘<=’’, ‘‘>’’, ‘‘>=’’ with ‘‘>=’’, ‘‘>’’, ‘‘<=’’, ‘‘<’’, respectively.
Valx converted the aforementioned two expressions extracted
from the example exclusion criterion to [‘‘Glucose’’, ‘‘<’’, 126.0,
‘‘mg/dL’’] and [‘‘HbA1c’’, ‘‘<=’’, 6.5, ‘‘%’’], respectively.
In a previously conducted evaluation of Valx for a paper under
preparation, the precision, recall, and F-measure for extracting
numeric expressions with the quantitative feature ‘‘HbA1c’’ were
99.6%, 98.1%, 98.8% for Type 1 diabetes trials, and 98.8%, 96.9%,
97.8% for Type 2 diabetes studies, respectively. The results of the
corresponding measures for extracting numeric expressions with
the quantitative feature ‘‘Glucose’’ were 97.3%, 94.8%, 96.1% for
Type 1 diabetes studies, and 92.3%, 92.3%, 92.3% for Type 2 diabetes
trials, respectively. We stored in COMPACT all the structured
numeric expressions extracted from eligibility criteria of all the
downloaded study summaries. These numeric expressions were
used in the eligibility feature frequency analysis module and the
distribution analysis module (described below).
2.2. The eligibility feature frequency analysis module
To provide the user with the list of frequently used eligibility
features in a condition-speciﬁc set of studies we built an eligibility
feature frequency analysis module. Given a condition and the num-
ber of frequent features to retrieve – ‘‘K’’, this module will analyze
the Kmost frequent qualitative and quantitative eligibility features
used by the studies on the selected condition. Multiple occurrences
of the same feature in a study are counted only once when comput-
ing the frequency. Given this information, when designing eligibil-
ity criteria for a new study, a user might reuse some of those
frequent features or verify whether a feature s/he considers impor-
tant is missing.
2.3. The query builder
The query builder module allows users to build a distribution
analysis query on a selected set of studies. After a user selects a fre-
quent quantitative feature of a condition-speciﬁc set of studies, the
query builder module will analyze (1) the distribution of number
of studies over the value spectrum of the quantitative feature
and (2) the distribution of studies by the values of a speciﬁc study
descriptor (e.g., study phase, intervention type). The distribution of
number of studies over the value spectrum of the chosen quantita-
tive feature allows the user to specify a narrower value range of
interest for closer investigation. In the query builder, the user must
specify (1) a value range (with an upper bound and a lower bound)
of the quantitative feature to be analyzed, (2) whether the distribu-
tion is on unbinned consecutive value points or binned non-over-
lapping value intervals, (3) whether the width of value intervals
is ﬁxed or varying.
Study descriptors are organized in categories, such as gender,
study type, intervention type, status, sponsor type, and phase. Each
descriptor value is followed by the percentage of selected studies
having that descriptor, which allows the user to estimate the num-
ber of studies to be included in the analysis. For example, if a userchooses ‘‘HbA1c’’ for Type 2 diabetes studies, s/he will see that
95.66% of these studies using ‘‘HbA1c’’ are interventional, whereas
4.29% are observational. A range of age and study start date can be
speciﬁed to further restrict the list of studies to analyze. The NCT
number of studies satisfying the query will be passed to the distri-
bution analysis module for further processing.
2.4. The distribution analysis module
Five types of distribution analyses are supported for each quan-
titative feature as described more fully below: (1) distribution of
number of studies over its unbinned consecutive value points or
non-overlapping value intervals within the user-speciﬁed value
range; (2) distribution of enrollment over its value points or value
intervals within the user-speciﬁed value range; (3) distribution of
number of studies over boundary values; (4) distribution of num-
ber of studies over permissible value ranges; and (5) distribution
of number of studies over permissible value range widths. In the
system, we grouped the analysis results of (3–5) together. The user
must choose one kind of distribution analysis at a time.
2.4.1. Distribution of number of studies
Distribution of number of studies reveals which parts of a quan-
titative feature’s permissible value range is widely or rarely per-
mitted across the selected studies. This module calculates the
distribution of the number of studies over consecutive value points
or non-overlapping value intervals of a quantitative feature within
the user-speciﬁed value range. If a user chooses to plot the distri-
bution of studies on unbinned value points, for each consecutive
value in the user-speciﬁed value range, we count the number of
studies for which patients having the value are eligible. Of note,
the distance between two consecutive value points can be ﬁxed
(i.e., the user-speciﬁed width) or varying (i.e., the actual boundary
values are the value points). If s/he chooses to plot on value inter-
vals, we count the number of studies for each value interval within
the user-speciﬁed value range. One study may cover multiple value
points or value intervals. If a user has speciﬁed a ﬁxed-width for
the value intervals and has picked multiple phases in the query
builder, s/he can stratify the distribution by multiple phases in
the same ﬁgure for comparison. If a user does not pick any phase,
studies of any phase (including those that do not specify a phase)
will be included in the analysis.
2.4.2. Distribution of enrollment
Distribution of enrollment presents the size of the target popu-
lation across the selected studies for value points or value intervals
of the quantitative feature. (In this paper, we do not distinguish
between actual and anticipated enrollment due to a data issue in
ClinicalTrials.gov. We will discuss this limitation later in Section 4.)
If a user chooses to plot the distribution of enrollment on consec-
utive value points, we sum the enrollment for the studies for which
patients having a speciﬁc value within the user-speciﬁed value
range are eligible to obtain the maximum enrollment. If s/he
chooses to plot by value intervals, for each interval in the user-
speciﬁed value range, we sum the enrollment for the studies in
the interval to obtain the maximum enrollment. To obtain the
average enrollment, for each value point or value interval, we
divide the corresponding maximum enrollment by the number of
studies. Distribution of enrollment can also be stratiﬁed by phases.
2.4.3. Distribution of number of studies over boundary values
The distribution of number of studies over boundary values
shows the most commonly used upper bound and lower bound
of a quantitative feature in selected studies. For this analysis, we
retrieve all the boundary values of the feature in the selected stud-
ies and count the number of studies for each boundary value. Then
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lower bound values. For open value range such as HbA1c >= 7%,
we only include one threshold value 7% in this analysis.
2.4.4. Distribution of number of studies over permissible value ranges
The distribution of the number of studies over permissible value
ranges highlights frequently used value ranges of the quantitative
feature in the selected studies. We itemize all the permissible value
ranges of the chosen quantitative feature in the selected studies,
count the number of studies that use each value range, and order
the result by the number of studies. In the case of open ranges,
we use inf or +inf as needed for the missing boundary value.
For example, BMI >= 15 kg/m2 is denoted as ‘‘[15,+inf)’’, whereas
HbA1c < 7.0% is denoted as ‘‘(inf, 7.0)’’. ‘‘[ ]’’ refers to being inclu-
sive, while ‘‘()’’ refers to being non-inclusive. Of note, in this anal-
ysis we do not consider studies that allow only a single value, e.g.,
the study NCT00519857 with an inclusion criterion ‘‘subjects were
to have a Body Mass Index (BMI) = 34 kg/m2.’’
2.4.5. Distribution of number of studies over permissible value range
widths
The value range width is the difference between the upper
bound and the lower bound of the selected quantitative feature
in a study. For example, the value range width of BMI derived from
the criterion ‘‘BMI value between 20 and 25 kg/m2’’ is 5 (=25  20).
This distribution reveals frequently used value range width. In this
analysis, we do not consider open value ranges such as
HbA1c >= 7.0%, because the difference of1 and 7.0 is not a deﬁnite
number.
2.5. Visualization module
The distribution analysis module passes the results of the distri-
bution analysis module to the visualization module. With Google
Charts API [54], we plot as line graphs the results of four out of
the ﬁve analyses described in the previous section: (1) distribution
of number of studies (Section 2.4.1), (2) distribution of maximum
and average enrollment (Section 2.4.2), (3) distribution of number
of studies over boundary values (Section 2.4.3), and (4) distribution
of number of studies over permissible value range widths (Sec-
tion 2.4.5). The line graphs are employed to visualize these four
analyses because (1) the x-axis values are non-overlapping, (2)
multiple curves can be drawn on the same line graph (e.g., to show
distribution of enrollment stratiﬁed by study phases, or distribu-
tion of boundary values stratiﬁed by upper bound values and lower
bound values), and (3) among all the ﬁgure types supported by
Google Chart API, the line graph is the most suitable ﬁgure type
to plot two-dimensional distributions of a continuous variable. In
contrast, because permissible value ranges of the different studies
are likely to be overlapping, we plot the distribution of number of
studies over permissible value ranges (Section 2.4.4) as a bar graph,
where the value ranges are displayed in descending order of fre-
quency. We leverage the applicable functions of the Google Charts
API to make the graphs interactive. A user may see the detail of the
analysis result by hovering the mouse cursor on the ﬁgure. Multi-
ple curves on the same ﬁgure are distinguished by different colors.
The user may hide a curve by clicking on its symbol in the legend.
The ranges of the x- and y-axes of the line graphs can scale itself
automatically to the currently visible curves. The user may zoom
in on a ﬁgure to investigate an area more closely or zoom out to
view the global pattern.
2.6. The Web-based prototype of VITTA
VITTA is a Web-based implementation of the aforementioned
methodology framework. We have made VITTA publicly availableat http://is.gd/VITTA. It has ﬁve pages for users to interact with:
i.e., (1) ‘‘condition and feature selection’’, (2) ‘‘query builder’’, and
three pages for visualization of the analysis results: (3) distribution
of number of studies, (4) distribution of enrollment, and (5) distri-
butions of number of studies over boundary values, permissible
value ranges and value range widths.
The ‘‘condition and feature selection page’’ has a dropdown
menu containing 1311 conditions pre-indexed by ClinicalTri-
als.gov. Currently, a user can choose only one value each time. A
user can type the ﬁrst letter of the condition for quick navigation.
After a user chooses a condition and speciﬁes the number of fre-
quent features to return, VITTA will analyze qualitative and quan-
titative eligibility features of the studies indexed to that condition
and display a certain number of them (speciﬁed by the user) in
separate sections in descending order of frequency. The qualitative
features are listed in a two-column table (one for inclusion, the
other for exclusion criteria) on the web page. Quantitative features
are listed in a dropdown menu that allows selection. Currently, our
analysis does not include a detailed view of qualitative features
beyond their frequency. After the user selects a quantitative fea-
ture, VITTA will analyze the characteristics of studies using the
quantitative feature and send the user to the ‘‘query builder page,’’
where the user can narrow his/her selection based on values of
study descriptors such as study type (interventional or observa-
tional), intervention type, study status, sponsor type, and phase.
After the user chooses a certain type of distribution analysis and
submit the query, s/he can view the analysis results online or
download a CSV ﬁle that includes NCT numbers and the data for
visualizing the results for ofﬂine analysis using MATLAB, R, etc.
On the result page, the user can also modify the query or start
again.2.7. Preliminary evaluation by potential users
In order to assess the user-perceived usefulness of VITTA, we
designed a questionnaire consisting of ﬁve Likert-scaled [55] mul-
tiple-choice questions and four open-ended questions. The ﬁve
multiple-choice questions adapted the well-adopted System
Usability Scale (SUS) [56,57], as shown in Table 3. Of the four
open-ended questions, two are about their current practice and
the other two are about VITTA. We recruited a convenience sample
of ﬁve potential users to perform a preliminary evaluation of
VITTA. These recruited users had a variety of backgrounds, includ-
ing three researchers from academia with specialties such as pedi-
atric, cardiology, and health IT usability evaluation as well as two
medical informaticians from pharmaceutical companies, and vari-
ous levels of involvement in clinical research. We conducted the
evaluation sessions either in the ofﬁce of the user or remotely
using WebEx. We ﬁrst gave a comprehensive demonstration of
VITTA to the users. Then the users tried the tool with their own
queries of interest.3. Results
We downloaded all 163,285 XML ﬁles of clinical study summa-
ries (one XML ﬁle for each study) registered on ClinicalTrials.gov as
of March 18, 2014. After excluding studies without eligibility crite-
ria, 162,586 records were further processed. Using Valx, we
extracted 97,560 distinct quantitative features from 682,718
numeric expressions from inclusion criteria and 89,555 distinct
quantitative features from 385,421 numeric expressions from
exclusion criteria. After unifying exclusion criteria and inclusion
criteria, there were in total 180,458 distinct quantitative features,
out of which 133 had each a frequency of more than 500.
Table 3
The usefulness questionnaire for VITTA.
Question type Question
number
Question
Multiple-
choice
1 When designing new studies, using VITTA may help me identify frequent value ranges of a quantitative feature for eligibility
determination
2 Using VITTA could help explain my rationale for subject selection more explicitly when designing new studies
3 I ﬁnd it easier to see global patterns of clinical study eligibility criteria design using VITTA
4 Assuming VITTA would be available on my job as a clinical trialist, I would use it in the future
5 I would prefer using VITTA tool for eligibility criteria design rather than manually ﬁnd similar studies on ClinicalTrials.gov
Open-ended 6 What is your current process for designing clinical study eligibility criteria?
7 What is the difﬁculty when designing clinical study eligibility criteria?
8 What do you see as potential value of VITTA for supporting clinical study designs?
9 Do you have any suggestions on improving VITTA?
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hosted as a MySQL database instance on Amazon Rational Data-
base Service, which is part of Amazon Web Services. The content
of COMPACT will be updated twice a year to reﬂect the changes
in ClinicalTrials.gov. The access to the COMPACT database is given
through the Web-based application VITTA described in this paper.3.1. Frequently used eligibility features and trend analysis
On the VITTA interface, users can review a list of the most fre-
quently used qualitative features, where users can select fre-
quently used quantitative features for further distribution
analysis. If a user chooses ‘‘diabetes mellitus’’ as the condition of
interest, the four most frequently used quantitative features are
age (52.89%), HbA1c (36.66%), BMI (32.40%), and Glucose
(14.32%). Some quantitative features might have been adopted
for participant selection only in recent years. Using a published
method for trend analysis of common data elements in clinical
study eligibility criteria [41,58], we analyzed the trend over time
of quantitative features used by studies of 1311 pre-indexed con-
ditions. Such information can help the designers of a new study
see possible changes in participant selection requirements in the
studies on a certain condition over a period of time and make
informed decisions when designing a new study. Using diabetes
as an example, we saw that the use of some quantitative features
changed signiﬁcantly over the past 15 years. Fig. 4 displays theFig. 4. Trend of (a) diastolic blood pressure and (b) systolic blood pressure in diabetes cli
while the vertical bars indicate Type 1 or Type 2 diabetes, respectively. Each blue marke
corresponding diabetes type for the corresponding year. The darker the shade of blue, t
year. (For interpretation of the references to colour in this ﬁgure legend, the reader is rtrend for (a) diastolic blood pressure, and (b) systolic blood pres-
sure. Since 2007, ‘‘diastolic blood pressure’’ and ‘‘systolic blood
pressure’’ have been used in eligibility criteria of studies in both
types of diabetes. In the future, we will display the trend of a fea-
ture on VITTA and allow the users to download the CSV ﬁles of the
trend analysis of a feature so they will be able to see the number of
studies using the feature in each year.3.2. Example distribution analysis queries
Hypertension and Type 2 diabetes are major medical conditions
that cause morbidity and mortality worldwide and are therefore
given global priorities in clinical research [59]. The eligibility fea-
ture frequency analysis module of VITTA identiﬁed BMI (Body
Mass Index) and HbA1c as representative quantitative features in
studies on hypertension and Type 2 diabetes, respectively. This
result is in accordance with the literature since BMI has been
shown to be closely associated with blood pressure [60,61]. HbA1c
test result reﬂects the average level of blood glucose over the pre-
vious three months [62]. Fig. 5 shows the frequent qualitative and
quantitative eligibility features if an investigator selects ‘‘diabetes
mellitus Type 2’’ as the condition. There are 3897 studies of Type
2 diabetes. HbA1c is used in 48.5% Type 2 diabetes studies, pre-
ceded by age with a marginally higher percentage (49.1%). BMI is
used in 8.51% hypertension studies, preceded by age and blood
pressure measures.nical studies from 1999 to 2013. The horizontal line indicates 15 years (1999–2013),
r indicates that the quantitative feature appears in at least 3% of the studies for the
he more frequently the quantitative feature is used in studies of the corresponding
eferred to the web version of this article.)
Fig. 5. The frequent qualitative and quantitative features of Type 2 diabetes studies.
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Table 4 shows the distribution by selected study descriptors on
the query builder page after an investigator chooses the quantita-
tive feature to be ‘‘HbA1c’’ for Type 2 diabetes studies or ‘‘BMI’’ for
hypertension studies. Note that some studies use ‘‘Phase 1/Phase
2’’ or ‘‘Phase 2/Phase 3’’ in the phase ﬁeld. When an investigator
selects ‘‘Phase 1’’, both ‘‘Phase 1’’ and ‘‘Phase 1/Phase 2’’ studies
are included for the distribution analyses.
Next we demonstrate the utility of VITTA using two sample
queries, which include the quantitative features ‘‘BMI’’ and
‘‘HbA1c’’ for conditions ‘‘hypertension’’ and ‘‘Type 2 diabetes,’’
respectively. Note that for each query, we only present a subset
of the ﬁgures that can be generated by VITTA.
3.2.2. Query 1: For interventional studies of hypertension using drug(s)
as intervention and using BMI as eligibility feature, what is the
distribution of number of studies stratiﬁed by phases 1/2/3/4 and the
distribution of enrollment on ﬁxed-width (0.5 kg/m2) value points of
BMI between 15 kg/m2 and 40 kg/m2?
There were 164 studies that satisﬁed the query (condition:
hypertension, study type: interventional, intervention type: drug,
phases: 1/2/3/4, quantitative eligibility feature: BMI, user-speciﬁed
value range: [15 kg/m2, 40 kg/m2]). Fig. 6(a) shows the distribution
of number of studies in different phases. The x-axis shows the con-
secutive value points of BMI of ﬁx-width (0.5 kg/m2), while the y-
axis shows the number of studies. Due to limited space, the
numeric labels of x-axis are not completely displayed. The distribu-
tion of maximum enrollment is shown in Fig. 6(b) where the y-axis
shows the maximum enrollment. The user can observe that more
participants with BMI value between 25 kg/m2 and 40 kg/m2 are
enrolled than those with BMI value between 15 kg/m2 and 25 kg/
m2. Comparing Fig. 6(a) and (b), we found that even though there
are similar numbers of studies recruiting patients with BMI values
between 19 kg/m2 and 25 kg/m2 and between 25 kg/m2 and 35 kg/
m2, the enrollment in studies requiring the ﬁrst range is noticeablysmaller than that of the latter. This is likely because individuals
with the latter range of BMI, which indicates overweight and obes-
ity [63], are at greater risk of hypertension [64]. Fig. 6(c) shows
that the average enrollment is gradually increasing with the
increasing value range of BMI. On average, phase 3 studies recruit
more patients with BMI greater than 27 kg/m2 than studies in
other phases.3.2.3. Query 2: For Type 2 diabetes industry-sponsored studies in
phases 1/2/3/4 that use HbA1c as eligibility feature and are recruiting,
what is the distribution of maximum enrollment for HbA1c of ﬁxed-
width (0.5%) value intervals of HbA1c between 1% and 12%? What is
the distribution of number of studies over boundary values,
permissible value ranges, and permissible value range widths?
For this query, VITTA analyzed 113 qualifying studies (condi-
tion: diabetes mellitus Type 2, status: recruiting, phases: 1/2/3/4,
sponsor type: industry, quantitative feature: HbA1c, user-speciﬁed
value range: [1%,12%]). The distribution of maximum enrollment is
displayed in Fig. 7(a). We can see that most Type 2 diabetes indus-
try-sponsored studies recruit patients with HbA1c values between
7.0% and 10.0%, which conforms to the ﬁnding in clinical practice:
HbA1c levels higher than 6.5% indicate diabetes [65]. Fig. 7(b)
shows the distribution of number of studies over boundary values.
To better display the modal upper and lower boundary values, we
hid the bimodal curve for the overall boundary values and left two
separated curves for the values used as upper bound or lower
bound, respectively. We can see that 7.0% is the most frequently
used lower bound, whereas 10.0% is the most frequently used
upper bound. Fig. 7(c) shows that the most used permissible value
range of HbA1c in the selected studies are [7.5,9.0] and [7.0,9.5].
Fig. 7(d) shows that ‘‘1.5’’ and ‘‘2.5’’ are the most used value range
widths in the selected studies that specify both an upper bound
and a lower bound of HbA1c.
Table 4
Distribution by selected descriptors of Type 2 diabetes studies using HbA1c and hypertension studies using BMI for participant selection.
Study characteristics Quantitative features
HbA1c (Type 2 diabetes) (n = 1890) BMI (hypertension) (n = 389)
Study type 1890 389
Interventional 1808 (95.66%) 356 (91.52%)
Observational 81 (4.29%) 33 (8.48%)
Observational [Patient Registry] 1 (0.05%) 0 (0%)
Expanded access 0 (0%) 0 (0%)
Intervention type 1833 362
Drug 1423 (77.63%) 212 (58.56%)
Procedure 51 (2.78%) 14 (3.87%)
Biological 20 (1.09%) 4 (1.10%)
Device 60 (3.27%) 10 (2.76%)
Behavioral 117 (6.38%) 58 (16.02%)
Dietary supplement 69 (3.76%) 35 (9.67%)
Genetic 8 (0.05%) 0 (0%)
Radiation 1 (0.05%) 0 (0%)
Other 92 (5.02%) 29 (8.01%)
Status 1890 389
Open studies 442 (23.39%) 105 (26.99%)
Recruiting 367 (19.42%) 81 (20.82%)
Not yet recruiting 75 (3.97%) 24 (6.17%)
Closed studies 1448 (76.61%) 284 (73.01%)
Active, not recruiting 135 (7.14%) 46 (11.83%)
Completed 1179 (62.38%) 210 (53.98%)
Withdrawn 18 (0.95%) 3 (0.77%)
Suspended 11 (0.58%) 1 (0.26%)
Terminated 95 (5.03%) 22 (5.66%)
Enrolling by invitation 10 (0.53%) 2 (0.51%)
Sponsor type 1890 389
NIH 19 (1.01%) 14 (3.60%)
Industry 1159 (61.32%) 135 (34.70%)
Other U.S. Federal Agency 13 (0.69%) 6 (1.54%)
Other 699 (36.98%) 234 (60.15%)
Phase 1890 389
0 9 (0.48%) 4 (1.03%)
1 166 (8.78%) 69 (17.74%)
2 292 (15.45%) 39 (10.03%)
3 539 (28.52%) 42 (10.80%)
4 400 (21.16%) 54 (13.88%)
Not applicable or not speciﬁed 408 (21.59%) 165 (42.42%)
Gender 1890 389
Both 1827 (96.67%) 330 (84.83%)
Male only 39 (2.06%) 22 (5.66%)
Female only 24 (1.27%) 37 (9.51%)
Study design – intervention model (for interventional studies) 1890 389
Parallel 1364 (72.17%) 199 (51.16%)
Factorial 28 (1.48%) 7 (1.80%)
Crossover 218 (11.53%) 97 (24.94%)
Single group 186 (9.84%) 53 (13.62%)
Not applicable or not speciﬁed 94 (4.97%) 33 (8.48%)
Study design – allocation (for interventional studies) 1890 389
Randomized 1595 (84.39%) 306 (78.66%)
Non-randomized 113 (5.98%) 19 (4.88%)
Not applicable or not speciﬁed 181 (9.58%) 64 (16.45%)
Study design – time perspective (for observational studies) 1890 389
Cross-sectional 12 (0.63%) 4 (1.03%)
Longitudinal 1 (0.05%) 1 (0.26%)
Prospective 64 (3.39%) 19 (4.88%)
Retrospective 64 (0.16%) 3 (0.77%)
Not applicable or not speciﬁed 1810 (95.77%) 362 (93.06%)
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Table 5 lists the results of the multiple-choice questions (Q1–
Q5) answered by ﬁve potential users in the preliminary evaluation.
The SUS-based score (4.6 + 4.2 + 4.0 + 4.2 + 4.6) ⁄ 4 = 86.4 suggests
the usefulness of VITTA for researchers involved in the design
and evaluation of clinical studies. It also conﬁrmed that this
method has the potential to help proﬁle aggregated target popula-tions for sets of studies and enable the generalizability analysis of
those studies.
Most of the ﬁve recruited potential users expressed keen inter-
est in using the tool for investigating eligibility criteria of existing
studies or for designing new studies. Regarding the current process
of designing clinical study eligibility criteria, User A ‘‘usually uses
literature search to ﬁnd similar studies.’’ User B said: ‘‘we always
make a team decision with domain experts,’’ and he usually ‘‘looks
Fig. 6. For consecutive BMI values, (a) distribution of studies in phases 1/2/3/4; (b) distribution of maximum enrollment for interventional drug studies on hypertension in
phases 1/2/3/4; (c) distribution of average enrollment for interventional drug studies on hypertension in phases 1/2/3/4.
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studies within the organization.’’ Regarding the difﬁculty encoun-
tered when designing clinical study eligibility criteria, User A
pointed out that ‘‘it is impossible to look at studies one by one to
design eligibility criteria.’’ User B ﬁnds it difﬁcult to ‘‘assess the pro-
tocol feasibility in terms of how many patients can be recruited from
the real world.’’ User C pointed at the ‘‘lack of uniformity of actual
criteria. There are multiple ways to say the same thing.’’ User D ‘‘ﬁnds
it difﬁcult to ﬁnd similar clinical studies.’’ Regarding the potentialvalue of VITTA, they noted that they would be able to learn from
large number of existing studies, which can save them a lot of time.
The ﬁve potential users collectively suggested that VITTA could
be used in the following scenarios: (1) to ﬁnd commonly used per-
missible value range(s) of a quantitative eligibility feature, (2) to
ﬁnd potentially under-represented target populations for clinical
studies, and (3) to support the rationale for using a certain value
range for grant applications. In terms of improvements for VITTA,
User C suggested the use of speciﬁc eligibility features, for exam-
Fig. 7. In industry-sponsored Type 2 diabetes studies in phases 1/2/3/4 that are recruiting, (a) distribution of maximum enrollment over HbA1c’s value intervals; (b)
distribution of number of studies over boundary values of HbA1c; (c) distribution of number of studies over permissible value ranges of HbA1c; (d) distribution of number of
studies over permissible value range widths of HbA1c.
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Table 5
The usefulness evaluation results (see Table 3 for the questions).
Question number Average score Strongly agree (5) (%) Agree (4) (%) Neutral (3) Disagree (2) Strongly disagree (1)
1 4.6 60 40
2 4.2 40 40 20%
3 4.0 40 40 20%
4 4.2 60 20 20%
5 4.6 60 40
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ciﬁc substance concepts. User E suggested aligning the workﬂow
with the development process of clinical studies.4. Discussion
Our results conﬁrmed the feasibility and usefulness of proﬁling
the quantitative eligibility features of the target populations of sets
of clinical studies. When complemented by similar work on quali-
tative features, our approach promises to enhance the ability to
characterize, understand, and improve clinical research generaliz-
ability. Our preliminary evaluation suggests that our method has
the potential to improve the accessibility of design patterns in eli-
gibility criteria through a global view of sets of clinical studies with
common characteristics. It is laborious and sometimes impossible
to obtain such a global view through manual review of many clin-
ical study summaries.
Our method also establishes a highly desirable prerequisite for
generalizability analyses of sets of clinical studies, which involve
comparisons between target populations and real-world patient
populations. A data-driven analytical system such as VITTA proﬁles
the distribution of the collective target populations in multiple
existing studies along the value spectrum of a selected quantitative
eligibility feature, and can potentially guide the participant selec-
tion of future studies in an interactive fashion. Stakeholders of clin-
ical trials can use VITTA to detect potential hidden eligibility
criteria design biases towards certain population subgroups at
the clinical research community level. For example, if most Type
2 diabetes mellitus trials require eligible patients to have their
A1c equal to or above 7%, investigation may be warranted to justify
why those patients whose A1c values are between 6.5% and 7% are
not considered for these trials. In the clinical trials research com-
munity, thresholds for blood pressure (e.g., 120 mmHg vs.
140 mmHg) for deﬁning hypertension or thresholds for A1c for
deﬁning pre-diabetic and diabetic population are still open
research topics. Tools like VITTA can effectively make transparent
the collective design trends among clinical trial designers.
Although we chose only two common conditions and their repre-
sentative quantitative features to illustrate our analytical frame-
work, VITTA is designed to support distribution analyses of any
quantitative feature of selected studies of any condition assuming
that the names and measurement units of all corresponding
numeric expressions are correctly recognized and parsed. The
modular design of VITTA enables ﬂexible customization of each
module for different tasks. For example, the core of the visualiza-
tion module can be replaced by D3 JavaScript library with more
interactive functionalities than Google Charts API. As summary
results of more and more studies are added to ClinicalTrials.gov
[66], we imagine that systematic reviewers could use VITTA to
identify studies of interest and to proﬁle their target populations
or study populations.4.1. Limitations
Quite a number of limitations are noteworthy in interpreting
this study. One caveat is that the current version of the quantita-tive feature extraction tool Valx [48] employed by this study needs
more formal evaluation and further improvement. Currently, even
though we have ﬁltered out many meaningless tags using pre-
deﬁned heuristics, the complexity and heterogeneity of free-text
eligibility criteria makes it a daunting task to unify all the quanti-
tative eligibility feature names and all the different measurement
units of a quantitative feature. In the future, we need more scalable
solutions to improve the accuracy of numeric expression parsing
for other quantitative features. In spite of the need to improve
the accuracy of the natural language processing (NLP) techniques
employed, instead of waiting for perfect NLP techniques, we pre-
sented this novel use of ‘‘good-enough’’ NLP results of clinical trial
summaries to motivate more NLP researchers to join our efforts in
extracting patterns from eligibility criteria text. The modular
design of VITTA makes it easy to provide more accurate distribu-
tion analysis results when more accurate parsing results are
updated in the COMPACT database.
Another limitation is that our method was designed speciﬁcally
for ClinicalTrials.gov, which does not include all studies world-
wide. Studies that are not subject to US law may be registered only
in the relevant countries. Many international studies registered in
their corresponding countries are included in the International
Clinical Trials Registry Platform (ICTRP) [67] managed by the
World Health Organization. Nevertheless, about 80% of studies in
ICTRP were also registered in ClinicalTrials.gov [23], indicating that
our analytical framework includes the majority of clinical study
summaries available on the Internet.
Many studies may have partial or condensed eligibility criteria
entered in ClinicalTrials.gov [68]. For some conditions, there might
not be a representative quantitative feature to proﬁle clinical study
target populations. When indexing studies for a condition, the
studies returned from ClinicalTrials.gov might include studies of
a similar but not the same condition. For example, a search on con-
dition ‘‘hypertension’’ will also retrieve studies on ‘‘pulmonary
hypertension’’ which is a different condition from hypertension
(high blood pressure). According to COMPACT, about 40% studies
in ClinicalTrials.gov did not specify their study phases. When a user
selects studies of a certain phase, some studies might be left out
because the phase information is not available or applicable. When
interpreting the distribution analysis results generated by VITTA,
the limitations in ClinicalTrials.gov itself should be taken into
account.
The last major limitation is that ClinicalTrials.gov deﬁnes only
one ﬁeld for ‘‘enrollment’’, which is initially used to indicate antic-
ipated enrollment before study starts but later used to indicate the
actual enrollment after the completion of the study. Therefore, the
meaning of this data ﬁeld is not stable throughout the study. We
suggest that both anticipated enrollment and actual enrollment
be reported separately for comparing the difference between target
populations and actually enrolled patient populations. This is a
design that can be incorporated to improve ClinicalTrials.gov.4.2. Ongoing and future work
Our future work along this line will focus on adding more study
descriptors of VITTA for selecting studies, e.g., interventions, spon-
254 Z. He et al. / Journal of Biomedical Informatics 54 (2015) 241–255sors, locations, etc. Currently, it only stratiﬁes the distribution of
studies or enrollment by phase. In the future, it will support study
stratiﬁcation using other study descriptors, e.g., study design,
recruiting status, etc. To test the feasibility of this system, we
recruited only a convenience sample of a small number of potential
users to evaluate the usefulness of VITTA. In the future, a larger and
more comprehensive evaluation with clinical investigators and
sponsors from both academia and industry can provide more
insights into their needs for the analysis of clinical study target
populations. We also acknowledge the limitation in proﬁling target
populations using only one quantitative feature each time. There-
fore, we are investigating analytical methods for proﬁling target
populations using multiple eligibility features simultaneously.
After incorporating the data of real patients, we also plan to ana-
lyze how the application order of eligibility criteria would affect
the cohort size, which might provide actionable knowledge to
accelerate patient recruitment.
5. Conclusions
We contribute a novel method for proﬁling the collective target
populations of sets of studies registered in ClinicalTrials.gov based
on quantitative eligibility features extracted from free-text eligibil-
ity criteria. The Web-based system VITTA enables interactive dis-
tribution analyses and visualization of frequently used eligibility
features. Our preliminary evaluation with a small number of
potential users demonstrated the potential of VITTA for improving
the transparency for participant selection for clinical research. This
method can also potentially help clinical trialists, patients, spon-
sors, and policy makers identify global patterns in eligibility crite-
ria in studies registered in ClinicalTrials.gov. In the future we will
conduct more evaluation studies to assess how VITTA can support
patient-centered outcomes research and improve the usability and
utility of VITTA based on user feedback accordingly.
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